Regulation of NFKB through the nuclear processing of p105 (NFKB1) in Epstein-Barr Virus immortalized B cell lines.

Transcription factors of the NF-κB/Rel family are retained in the cytoplasm as inactive complexes through association with IκB inhibitory proteins. Several NF-κB activators induce the proteolysis of IκB proteins, which results in the nuclear translocation and DNA binding of NF-κB complexes. Here, we report a novel mechanism of NF-κB regulation mediated by p105 (NF-κB1) precursor of p50 directly at the nuclear level. In Epstein- Barr virus-immortalized B cells, p105 was found in the nucleus, where it was complexed with p65. In concomitance with NF-κB activation, mitomycin C induced the processing of p105 to p50 in the nucleus, while it did not affect the steady-state protein levels of IκBα and p105 in the cytoplasm. Differently, phorbol 12-myristate 13-acetate induced a significant proteolysis of both IκBα and p105 in the cytoplasm, while it did not affect the protein level of p105 in the nucleus. These results suggest that in Epstein-Barr virus-positive B cell lines the nuclear processing of p105 can contribute to NF-κB activation in response to specific signaling molecules, such as DNA-damaging agents

An NF-kB site in the 5'-untraslated leader region of the Human Immunodeficiency virus type 1 enhances the viral expression in response to NF-kB-activating stimuli.

The 5'-untranslated leader region of human immunodeficiency virus, type 1 (HIV-1), includes a complex array of putative regulatory elements whose role in the viral expression is not completely understood. Here we demonstrate the presence of an NF-κB-responsive element in the trans- activation response (TAR) region of HIV-1 that confers the full induction of HIV-1 long terminal repeat (LTR) in response to NF-κB-activating stimuli, such as DNA alkylating agents, phorbol 12-myristate 13-acetate, and tumor necrosis factor-α. The TAR NF-κB site GGGAGCTCTC spans from positions +31 to +40 and cooperates with the NF-κB enhancer upstream of the TATA box in the NF-κB-mediated induction of HIV-1 LTR. The conclusion stems from the following observations: (i) deletion of the two NF-κB sites upstream of the TATA box reduces, but does not abolish, the HIV-1 LTR activation by NF-κB inducers; (ii) deletion or base pair substitutions of the TAR NF-κB site significantly reduce the HIV-1 LTR activation by NF-κB inducers; (iii) deletions of both the NF-κB sites upstream of the TATA box and the TAR NF- κB site abolish the activation of HIV-1 LTR in response to NF-κB inducers. Moreover, the p50·p65 NF-κB complex binds to the TAR NF-κB sequence and trans-activates the TAR NF-κB-directed expression. The identification of an additional NF-κB site in the HIV-1 LTR points to the relevance of NF-κB factors in the HIV-1 life cycle

Safety of B. abortus rough mutant strain RB51 administration in Buffalo cows

The objective of this study was to determine if B. abortus rough mutant strain RB51 is eliminated in Buffalo milk. Five milk buffaloes were inoculated with the triple of the recommended calfhood dose (3.0 – 10.2 x 1010 cfu/ml) of B. abortus RB51 strain by subcutaneous route in the right axillary region. Milk samples were taken aseptically on a daily basis for the first 30 days and weekly for the second and third months. The samples were inoculated on Brucella Medium Base (BMB) (Oxoid) and Rifampin Brucellae Medium (RBM) and incubated under 10% CO2 at 37°C for 10 days. The suspicious colonies were recultured in BMB and RBM. PCR analysis was also performed on milk samples. There were no isolations of bacteria with characteristics of Brucella from any of the milk samples collected during 90 days of the study. However Brucella RB51 DNA was detected on day 2 and 3 post vaccination in one buffalo cow and on day 21 post vaccination in another buffalo cow. It was concluded that the strain used at this dose wasn't eliminated by milk in Buffaloes inoculated during lactation, however PCR positive results underline the necessity of milk pasteurization in order to minimize food-chain exposure

Molecular targets of developmental exposure to bisphenol A in diabesity: a focus on endoderm-derived organs

Several studies associate foetal human exposure to bisphenol A (BPA) to metabolic/endocrine diseases, mainly diabesity. They describe the role of BPA in the disruption of pancreatic beta cell, adipocyte and hepatocyte functions. Indeed, the complexity of the diabesity phenotype is due to the involvement of different endoderm-derived organs, all targets of BPA. Here, we analyse this point delineating a picture of different mechanisms of BPA toxicity in endoderm-derived organs leading to diabesity. Moving from epidemiological data, we summarize the in vivo experimental data of the BPA effects on endoderm-derived organs (thyroid, pancreas, liver, gut, prostate and lung) after prenatal exposure. Mainly, we gather molecular data evidencing harmful effects at low-dose exposure, pointing to the risk to human health. Although the fragmentation of molecular data does not allow a clear conclusion to be drawn, the present work indicates that the developmental exposure to BPA represents a risk for endoderm-derived organs development as it deregulates the gene expression from the earliest developmental stages. A more systematic analysis of BPA impact on the transcriptomes of endoderm-derived organs is still missing. Here, we suggest in vitro toxicogenomics approaches as a tool for the identification of common mechanisms of BPA toxicity leading to the diabesity in organs having the same developmental origin

Effect of mannan oligosaccharides on rabbit performance, digestibility and rectal Bacterial anaerobic populations during an episode of epizootic rabbit enteropathy

[EN] The effect of three levels of mannan oligosaccharides (MOS at 0.5, 1.0 and 1.5 g/kg diet) compared to dietary antibiotic supplementation (ANT, colistin sulphate 144, tylosin 100 and oxytetracycline 1000 ppm) and to a diet without MOS or medication (control group) were studied on 5 groups of rabbits (n=342 cages/group and 2 rabbits/cage) from weaning (35 d) to 60 d of age in a farm with an anamnestic history of Epizootic Rabbit Enteropathy (ERE). Mortality rate was recorded daily. Thirty two cages per group were randomly chosen to record growth performance and rectal anaerobic microbial population. Live weight and feed intake were recorded weekly. At 49 d of age rectal swabs were collected with cotton swabs from 8 rabbits per group and the anaerobic microbial population was counted. Feed digestibility was determined per cage using acid insoluble ash as an internal marker, collecting faeces from 57 to 59 d of age. An episode of ERE occurred during the second and the third week of the trial. The control group showed a high mortality rate during the fattening period (78%) and was not considered for further measurements. Total mortality rate was higher (P<0.05) for rabbits fed antibiotics (34.2%) than for those fed MOS (17.7, 7.75 and 17.1 %, for MOS at 0.5, 1.0 and 1.5 g/kg diet, respectively), with the lowest mortality rate being for those with a 1.0 g MOS/kg diet. Medicated rabbits showed similar growth rates compared to the average of those fed MOS diets (38.6 g/d on average), but impaired feed conversion ratio (FCR) and nutrient digestibility (P<0.003). Rabbits fed MOS at 1.0 g/kg showed better growth rates, FCR and nutrient digestibility (P<0.01) than those fed 1.5 g/kg MOS. Total anaerobic and Clostridium spp. counts were higher in medicated animals compared to those fed MOS, with those fed 1 g/kg MOS showing the lowest value (P<0.001). Under critical conditions due to an episode of ERE, a concentration of 1.0 g/kg MOS in the diet, could reduce rabbit mortality and improve growth performance.Bovera, F.; Nizza, A.; Marono, S.; Mallardo, K.; Piccolo, G.; Tudisco, R.; De Martino, L.... (2010). Effect of mannan oligosaccharides on rabbit performance, digestibility and rectal Bacterial anaerobic populations during an episode of epizootic rabbit enteropathy. World Rabbit Science. 18(1):9-16. doi:10.4995/wrs.2010.18.0291618

The expression of inhibitor of bruton's tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis.

Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy with a variable clinical outcome. Biomarkers of CLL progression are required for optimising prognosis and therapy. The Inhibitor of Bruton's tyrosine kinase-isoform α (IBTKα) gene encodes a substrate receptor of Cullin 3-dependent E3 ubiquitin ligase, and promotes cell survival in response to the reticulum stress. Searching for novel markers of CLL progression, we analysed the expression of IBTKα in the peripheral blood B-cells of CLL patients, before and after first line therapy causing remission. The expression of IBTKα was significantly increased in disease progression, and decreased in remission after chemotherapy. Consistently with a pro-survival action, RNA interference of IBTKα increased the spontaneous and Fludarabine-induced apoptosis of MEC-1 CLL cells, and impaired the cell cycle of DeFew B-lymphoma cells by promoting the arrest in G0/G1 phase and apoptosis. Consistently, RNA interference of IBTKα up regulated the expression of pro-apoptotic genes, including TNF, CRADD, CASP7, BNIP3 and BIRC3. Our results indicate that IBTKα is a novel marker of CLL progression promoting cell growth and resistance to apoptosis. In this view, IBTKα may represent an attractive cancer drug target for counteracting the therapy-resistance of tumour cells

Non-coding RNAs change their expression profile after Retinoid induced differentiation of the promyelocytic cell line NB4

<p>Abstract</p> <p>Background</p> <p>The importance of non-coding RNAs (ncRNAs) as fine regulators of eukaryotic gene expression has emerged by several studies focusing on microRNAs (miRNAs). miRNAs represent a newly discovered family of non coding-RNAs. They are thought to be crucial players of human hematopoiesis and related tumorigenesis and to represent a potential tool to detect the early stages of cancer. More recently, the expression regulation of numerous long ncRNAs has been linked to cell growth, differentiation and cancer although the molecular mechanism of their function is still unknown.</p> <p>NB4 cells are promyelocytic cells that can be induced to differentiation upon retinoic acid (ATRA) treatment and represent a feasible model to study changes of non coding RNAs expression between cancer cells and their terminally differentiated counterpart.</p> <p>Findings</p> <p>we screened, by microarray analysis, the expression of 243 miRNAs and 492 human genes transcribing for putative long ncRNAs different from miRNAs in NB4 cells before and after ATRA induced differentiation. Our data show that 8 miRNAs, and 58 long ncRNAs were deregulated by ATRA induced NB4 differentiation.</p> <p>Conclusion</p> <p>our data suggest that ATRA-induced differentiation lead to deregulation of a large number of the ncRNAs that can play regulatory roles in both tumorigenesis and differentiation.</p

Insights into Thymus Development and Viral Thymic Infections

T-cell development in the thymus is a complex and highly regulated process, involving a wide variety of cells and molecules which orchestrate thymocyte maturation into either CD4+ or CD8+ single-positive (SP) T cells. Here, we briefly review the process regulating T-cell differentiation, which includes the latest advances in this field. In particular, we highlight how, starting from a pool of hematopoietic stem cells in the bone marrow, the sequential action of transcriptional factors and cytokines dictates the proliferation, restriction of lineage potential, T-cell antigen receptors (TCR) gene rearrangements, and selection events on the T-cell progenitors, ultimately leading to the generation of mature T cells. Moreover, this review discusses paradigmatic examples of viral infections affecting the thymus that, by inducing functional changes within this lymphoid gland, consequently influence the behavior of peripheral mature T-lymphocytes

Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients

Background Nivolumab is an anti-PD1 antibody that has dramatically improved metastatic melanoma patients’ outcomes. Nevertheless, many patients are resistant to PD-1 inhibition, occasionally experiencing severe of-target immune toxicity. In addition, no robust and reproducible biomarkers have yet been validated to identify the correct selection of patients who will beneft from anti-PD-1 treatment avoiding unwanted side efects. However, the strength of CD26 expression on CD4+ T lymphocytes permits the characterization of three subtypes with variable degrees of responsiveness to tumors, suggesting that the presence of CD26-expressing T cells in patients might be a marker of responsiveness to PD-1-based therapies. Methods The frequency distribution of peripheral blood CD26-expressing cells was investigated employing multiparametric fow cytometry in 69 metastatic melanoma patients along with clinical characteristics and blood count parameters at baseline (W0) and compared to 20 age- and sex-matched healthy controls. Percentages of baseline CD4+CD26high T cells were correlated with the outcome after nivolumab treatment. In addition, the frequency of CD4+CD26high T cells at W0 was compared with those obtained after 12 weeks (W1) of therapy in a sub-cohort of 33 patients. Results Circulating CD4+CD26high T cells were signifcantly reduced in melanoma patients compared to healthy subjects (p=0.001). In addition, a signifcant association was observed between a low baseline percentage of CD4+CD26high T cells (<7.3%) and clinical outcomes, measured as overall survival (p=0.010) and progression-free survival (p=0.014). Moreover, patients with clinical beneft from nivolumab therapy had signifcantly higher frequencies of circulating CD4+CD26high T cells than patients with non-clinical beneft (p=0.004) at 12 months. Also, a higher pre-treatment proportion of circulating CD4+CD26high T cells was correlated with Disease Control Rate (p=0.014) and best Overall Response Rate (p=0.009) at 12 months. Interestingly, after 12 weeks (W1) of nivolumab treatment, percentages of CD4+CD26high T cells were signifcantly higher in comparison with the frequencies measured at W0 (p<0.0001), aligning the cell counts with the ranges seen in the blood of healthy subjects